293 related articles for article (PubMed ID: 26381407)
1. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
2. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
Chang CC; Campoli M; Restifo NP; Wang X; Ferrone S
J Immunol; 2005 Feb; 174(3):1462-71. PubMed ID: 15661905
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic changes within the promoter regions of antigen processing machinery family genes in Kazakh primary esophageal squamous cell carcinoma.
Sheyhidin I; Hasim A; Zheng F; Ma H
Asian Pac J Cancer Prev; 2014; 15(23):10299-306. PubMed ID: 25556465
[TBL] [Abstract][Full Text] [Related]
4. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
5. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
6. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines.
Hurks HM; Metzelaar-Blok JA; Mulder A; Claas FH; Jager MJ
Int J Cancer; 2000 Mar; 85(5):697-702. PubMed ID: 10699951
[TBL] [Abstract][Full Text] [Related]
7. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin DJ; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
J Clin Invest; 1998 Jun; 101(12):2720-9. PubMed ID: 9637706
[TBL] [Abstract][Full Text] [Related]
8. Differential contribution of TAP and tapasin to HLA class I antigen expression.
Belicha-Villanueva A; McEvoy S; Cycon K; Ferrone S; Gollnick SO; Bangia N
Immunology; 2008 May; 124(1):112-20. PubMed ID: 18194274
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
10. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
11. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
[TBL] [Abstract][Full Text] [Related]
12. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.
Wang Z; Marincola FM; Rivoltini L; Parmiani G; Ferrone S
J Exp Med; 1999 Jul; 190(2):205-15. PubMed ID: 10432284
[TBL] [Abstract][Full Text] [Related]
13. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.
Wang Z; Margulies L; Hicklin DJ; Ferrone S
Tissue Antigens; 1996 May; 47(5):382-90. PubMed ID: 8795138
[TBL] [Abstract][Full Text] [Related]
14. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
15. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.
Chang CC; Ogino T; Mullins DW; Oliver JL; Yamshchikov GV; Bandoh N; Slingluff CL; Ferrone S
J Biol Chem; 2006 Jul; 281(27):18763-73. PubMed ID: 16648140
[TBL] [Abstract][Full Text] [Related]
16. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Respa A; Bukur J; Ferrone S; Pawelec G; Zhao Y; Wang E; Marincola FM; Seliger B
Clin Cancer Res; 2011 May; 17(9):2668-78. PubMed ID: 21248298
[TBL] [Abstract][Full Text] [Related]
17. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
Hayashi T; Kobayashi Y; Kohsaka S; Sano K
Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
[TBL] [Abstract][Full Text] [Related]
18. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
[TBL] [Abstract][Full Text] [Related]
19. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Donia M; Harbst K; van Buuren M; Kvistborg P; Lindberg MF; Andersen R; Idorn M; Munir Ahmad S; Ellebæk E; Mueller A; Fagone P; Nicoletti F; Libra M; Lauss M; Hadrup SR; Schmidt H; Andersen MH; Thor Straten P; Nilsson JA; Schumacher TN; Seliger B; Jönsson G; Svane IM
Cancer Res; 2017 Sep; 77(17):4562-4566. PubMed ID: 28655789
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of human melanoma antigen expression by IFN-beta.
Dunn IS; Haggerty TJ; Kono M; Durda PJ; Butera D; Macdonald DB; Benson EM; Rose LB; Kurnick JT
J Immunol; 2007 Aug; 179(4):2134-42. PubMed ID: 17675472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
